2023 April 21, CommBio's CEO Dr. Bin Xiang presents at the 2023 Synthetic Biology Carnival in Nanjing, where he discusses R&D of engineered bacteria therapeutics (bacterial vector gene therapy).
2023 January 14, CommBio's CSO Dr. Peter Atadja tells his story of living and working in Zhangjiang as a foreign scientist and researcher.
2022 December 30, CommBio and the Shanghai Center of Biomedicine Development launch joint laboratory for bacterial vector gene therapy quality research and signs collaboration agreement in translation.
2022 November 21, CommBio and the Shanghai Cancer Institute launch joint laboratory to explore and research nanomedicine and bacterial vector gene therapy.
2022 October 20, CommBio appoints Dr. Peter Atadja as Chief Scientific Officer. Dr. Atadja will lead all pre-clinical research work of CommBio’s bacterial vector gene therapy programs.
CommBio Therapeutics Co., Ltd 沪ICP备2021004953号-1